Connect with us

News

Femtech versus ovarian cancer – an update

Published

on

Ovarian cancer is the sixth most common cancer in women, with around 7,500 new cases per day.

According to Cancer Research UK statistics, ovarian cancer survival is improving, having almost doubled in the last 40 years. In the 1970s, less than a fifth of women diagnosed with ovarian cancer survived their disease beyond ten years, now it’s more than a third.

However, with a range of non-specific symptoms, including feeling full quickly, bloating and stomach pain, it can be hard to diagnose.

In some cases, it can also cause unexplained tiredness or weight loss, or changes in your bowel habit especially if this starts after the age of 50.

However, as technology is constantly evolving to help us detect, treat and cure more diseases than ever before, can femtech helping to continue the fight against ovarian cancer?

Femtech World reports.

Screening

Recent research has led scientists to believe that the cervical screening programme could also be used to screen for both ovarian and breast cancers.

Experts say they may have found tell-tale signatures in these neck-of-the-womb cells linked to other cancers, although further research is needed.

Cells that turn cancerous often show distinctive early changes at the molecular level.

And researchers believe they have found some in smear-test samples that could help identify women at higher risk of specific other cancers, not just of the cervix.

Dr Julie Sharp, from Cancer Research UK, said: “Screening for cervical cancer is already an invaluable tool, so it’s interesting to see if cell samples taken through screening could be used in future to detect other cancers.

“However, we need further research to see how accurate this method is at detecting women with ovarian and breast cancer.

“Like the authors of this research, we look forward to seeing larger trials over longer periods to establish whether cervical cells could diagnose other cancers at an earlier stage.”

The work was funded by The Eve Appeal research charity that hopes to drive improved treatments for gynecological cancers.

Early detection

When diagnosed at its earliest stage, almost all women with ovarian cancer will survive their disease for one year or more, compared with slightly more than one in two people when the disease is diagnosed at the latest stage – highlighting just how important early detection is.

Israeli femtech start-up GinaLife is developing a platform of biomarker strategies, supported by artificial intelligence and data science, for the early detection of problems in women’s health.

It was set up by research scientist Inbal Zafir-Lavie, after her 38-year-old sister died from colorectal cancer, which, due to her young age, remained undiagnosed until it was too late.

GinaLife is currently developing a test that can analyse vaginal fluids, using artificial intelligence and data science to search for specific cancer biomarkers. While it is being tested at first in-clinic, the company envisions one day it will be available for home or remote use, increasing accessibility and potentially saving more lives.

In another early detection breakthrough, Boston-based start-up AOA is developing the first non-invasive ovarian cancer diagnostic liquid biopsy test, which could save the lives of half the women who are diagnosed with ovarian cancer.

That’s because, by the time they are diagnosed, in many cases the cancer has already spread.

AOA’s Akrivis GD is a liquid biopsy test that shows promising results in the early diagnosis of ovarian cancer through analysis of tumour marker gangliosides, which can therefore lead to earlier diagnosis and earlier treatment.

Research

University of Arizona researchers have developed a new device to help learn more about ovarian cancer, as well as supporting earlier diagnosis.

The university’s BIO5 Institute Director Jennifer Barton has developed a high-resolution falloposcope, which has a diameter of only 0.8 mm, small enough to image the fallopian tubes – narrow ducts that connect the uterus to the ovaries – and search for signs of early-stage cancer.

Since September last year, human trial, Dr John Heusinkveld has been using the device to image the fallopian tubes of volunteers who are already having their tubes removed for non-cancer reasons. This will allow researchers not only to test the effectiveness of the device, but also to start establishing a baseline of what “normal” fallopian tubes look like.

Researchers believe ovarian cancer usually starts in the fallopian tubes, and many medical professionals recommend that at-risk women have their ovaries and fallopian tubes removed.

However, the procedure pushes women into surgically induced menopause, with side effects including hot flushes, mood swings, and higher risk of heart and bone disease

Barton cited one example of a study in which 122 patients who were known to carry genes that increased their risk for cancer had their fallopian tubes removed as a precaution. Analysis of the tubes later showed that only seven of the women were in the process of developing cancer.

News

Lawyers warn of discrimination risks around lack of menstrual health support in the workplace

Employers should consider proactively supporting women in managing menstruation at work, lawyers have argued

Published

on

Employers should consider the potential discrimination risks around menstrual health in the workplace, lawyers have warned, as research shows that most women in the UK feel unsupported.

According to the Chartered Institute of Personnel and Development (CIPD), the majority of women in the UK do not feel a strong sense of support in their organisation in relation to their menstrual cycle.

Figures show women are more likely to feel supported by colleagues than by their employer or manager, with only one in 10 reporting that their organisation provides support for menstruation and menstrual health.

Annisa Khan, employment lawyer at Farrer & Co who has previously raised the alarm over the lack of practical measures to support women with their periods, told Femtech World that employers should be mindful of the legal risks related to managing menstruation.

“Under the Equality Act 2010, it is unlawful to discriminate against employees based on sex, age, or disability,” she said.

“Employers should therefore consider the potential discrimination risks in relation to managing mensuration in the workplace and implement measures to reduce these risks.”

A lack of workplace period policies has been estimated to cost businesses over £6bn per year, as menstrual symptoms cause women to miss an average of 8.4 days per year due to lower productivity.

Khan said organisations should consider proactively supporting employees in managing menstruation at work by reviewing existing policies, including sickness absence and health and wellbeing policies, to ensure they effectively address menstrual-related concerns.

“Creating an open and supportive environment is crucial for employees to feel comfortable discussing periods at work,” she explained.

“This involves raising awareness among all staff, including senior-level managers and male colleagues, to foster an understanding of how colleagues may be affected by menstruation, the relevant policies and how to have open and empathetic conversations.

“Implementing practical measures is also essential to create a supportive environment. Practical steps can include having accessible bathroom facilities with sanitary bins, providing free period products to employees, offering additional breaks and providing a quiet space for rest.”

In line with CIPD’s findings, Khan said workplaces should also consider implementing more flexible working practices and giving women more breaks when needed.

“Employers should be open to employees adjusting their work pattern on the days they are experiencing menstruation symptoms by, for example, offering employees the opportunity to work from home.

“Additionally, they should consider the needs of employees with disabilities or those with medical conditions, and how they may be affected by managing mensuration at work.”

Heidi Watson, employment partner at Clyde & Co, said employers should ensure they avoid breaching discrimination laws when approaching issues like menstrual health.

“As awareness of menstrual issues such as endometriosis grows and as employees are more willing to discuss their symptoms at work, employers will need to consider whether employees are disabled under the legal definition and therefore entitled to protection from less favourable treatment and subject to the duty of the employer to make reasonable adjustments for them,” she told Femtech World.

“Employees may also be able to establish sex or age discrimination claims. We can expect more claims to come before the Employment Tribunal in the not too distant future, in a similar way as we have seen with cases involving menopause in recent years.

“Adopting a flexible approach to managing those with menstrual symptoms which are impacting their work, and creating an open and supportive culture around the issue, will help to reduce the risk of such claims being brought,” she added.

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

OB/GYN-founded vitamin company pledges US$10m to improve women’s health research

Perelel aims to close the divide on women’s reproductive health research and improve access to nutritional support

Published

on

Alex Taylor and Victoria Thain Gioia, co-founders of Perelel

The US OB/GYN-founded vitamin company Perelel has pledged US$10m to Magee-Womens Research Institute and Good+ Foundation to fund women’s health research and address gaps in maternal healthcare.

The vitamin company said the US$10m would be distributed as both in-kind product donations and funding grants through 2027 focused on advancing women’s reproductive health.

Magee-Womens Research Institute is the largest US research foundation focused exclusively on women’s health, reproductive biology and infant research and care.

Good+Foundation is a national nonprofit working to dismantle multi-generational poverty by pairing tangible goods with innovative services for under-resourced individuals.

“As the only female OB/GYN-founded women’s vitamin company, Perelel is committed to ensuring that all women have access to medically backed care,” said Victoria Thain Gioia, co-founder and co-CEO of Perelel.

“This is why we are devoted to furthering women’s research in partnership with Magee-Womens Research Institute and creating more equity in the way underserved communities receive critical prenatal micronutrients that would otherwise be inaccessible thanks to Good+Foundation.”

Research shows that medical studies have historically excluded female participants and data have been collected from males and generalised to females.

The exclusion of women of “childbearing potential” from clinical research studies has meant that women’s diseases are often missed, misdiagnosed or remain a total mystery.

Alex Taylor, co-founder and co-CEO and of Perelel, said: “We recognise how wildly complex women’s bodies are — bodies that have historically been oversimplified, objectified and shamefully under-researched in medicine.

“Unfortunately, it’s not as simple as ’12 essential nutrients.’ In founding Perelel, we hope to shine a light on how dynamic our bodies are by supporting them with targeted solutions made by the doctors and experts who know best.

“Core to what we stand for is the need to keep fighting for our fundamental rights and help close the women’s health research gap and improve body literacy.”

Perelel’s pledge comes at a time of intensified focus on women’s health as efforts start to reach new levels, including the White House, after President Joe Biden announced the first-ever initiative on Women’s Health Research in 2023.

“It is critical that there is more in-depth medical research done to support women at every hormonal life stage,” said Michael Annichine, CEO at Magee-Womens Research Institute and Foundation.

“Perelel has committed to a cash donation to further advance research into women’s reproductive health and to ensure that this research is made more accessible to doctors everywhere.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

New treatment could ‘disrupt’ growth of breast cancer tumours

A new type of immunotherapy could lead to pioneering treatment for breast cancer

Published

on

A breakthrough injection could “disrupt” the growth of breast cancer tumours, paving the way for a pioneering new treatment.

Breast cancer is the most common cancer in the UK with one woman diagnosed every 10 minutes. Around 55,000 women in the UK are diagnosed with breast cancer every year and 11,500 die from the disease each year.

Researchers from the Institute of Cancer Research have found that a new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumours.

The discovery, published in The Journal for ImmunoTherapy of Cancer, has found that an immunotherapy approach targeting a protein, called endosialin, disrupts the tumour’s blood supply and, as a result, can hinder its growth and spread.

Unlike most cancer treatments, this innovative treatment does not target cancer cells directly but attacks the cells that support the disease instead.

Researchers used a type of immunotherapy called CAR-T therapy, which involves removing a patient’s healthy immune cells and genetically modifying them to attack specific targets.

CAR-T therapies are already being used to treat some blood cancers, and scientists are trying to find ways to make them effective for other types of cancer, including breast cancer.

However, CAR-T cell therapy does not always work on tumours because their environment suppresses the immune response, and it can also be challenging to find specific features on the breast cancer cells to target.

To work around these challenges, the team directed the CAR-T cells to cells surrounding the tumour’s blood supply that make the endosialin protein, rather than actual cancer cells. In experiments in mice, scientists found that targeting endosialin successfully reduced the breast cancer’s growth and spread.

The team, based at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research (ICR), also tested the treatment on lung cancer tumours in mice and saw similarly successful results, suggesting patients with other types of cancer could benefit from this new treatment too.

In addition, researchers found that the CAR-T therapy did not affect cells without endosialin, indicating this could work as a cancer-specific treatment with potentially fewer side effects for patients.

“This is the very first study that demonstrates the effectiveness of using endosialin-directed CAR-T cells to reduce breast cancer tumour growth and spread,” said Dr Frances Turrell, study co-leader and postdoctoral training fellow in the division of breast cancer research at the Institute of Cancer Research.

“Immunotherapy has had limited success in treating breast cancer but by targeting the cells that support the tumour and help it to survive, rather than the cancer cells directly, we’ve found a promising way to overcome the challenges posed by the tumour environment and develop a more effective and targeted treatment for breast cancer.

“We could not have done this project without funding to the Molecular Cell Biology group from Breast Cancer Now and we hope that further research will help translate these findings into targeted therapies for breast cancer patients.”

Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: “This exciting research could lead to much-needed targeted treatments for people with breast cancer, and with one person dying from breast cancer every 45 minutes in the UK, new treatments like these are urgently needed.

“Now we know that the treatment works in principle in mice, Breast Cancer Now researchers can continue to develop this immunotherapy to make it suitable for people, as well as to understand the full effect it could have and who it may benefit the most.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.